---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104557"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:30:05.618708+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Rapport Therapeutics Q2 net loss $26.7M; RAP-219 Phase 2a topline due Sept 2025, cash runway through 2026

## Summary
- Net loss of $26.7M for Q2 2025 vs $18.1M YoY; R&D expenses $22.7M and G&A $6.8M.
- RAP-219 Phase 2a trial in drug-resistant focal onset seizures fully enrolled; topline results expected September 2025.
- Phase 2 trial of RAP-219 in bipolar mania initiated; topline results anticipated first half of 2027.
- Cash, equivalents, and short-term investments $260.4M as of June 30, 2025, sufficient to fund operations through end of 2026.
- Phase 1 safety: no SAEs; all TEAEs Grade 1 or 2; most common headache (n=12), dry mouth (5), brain fog (5), fatigue (5).

## SEC filing metadata
- accession: 0000950170-25-104557
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/0000950170-25-104557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/rapp-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104557
- JSON: https://secwatch.observer/filing/0000950170-25-104557.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.